Hmm. Pretty hysterical today, aren't we?

Newsgroup Leader Katheen · medicine forum Guru Joined: 20 Jan 2006 Posts: 654

Was it something I said?

Kathleen

http://actionlyme.org/THE_CENTRAL_LYME_RICO_PATENTS.htm

How to verify- How to use the US Patent Database:

http://www.uspto.gov/index.html US Patent Office

http://patft1.uspto.gov/netahtml/PTO/search-bool.html Main Search page

http://patft1.uspto.gov/netahtml/PTO/srchnum.htm Patent Number Search
page

=======================

THE CRIME

1) Yale explains how LYMErix does not work:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8500891&query_hl=4&itool=pubmed_DocSum

2) Yale not using DNA primers for flagellin to determine OspA "works":
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1608951&query_hl=4&itool=pubmed_DocSum

'Should not have used immunofluorescing antibodies, because
OspA would no longer be expressed, in response to
"selection pressure"

3) Yale discussing how LYMErix does not prevent Lyme because of the
selection pressure, which essentially means that Lyme is a relapsing
fever borreliosis, since they all are relapsing fever borrelioses. 4
days previously Yale applied for the LYMErix patent- even though they
knew LYMErix did not work,

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=7729870%5BUID%5D

THE PATENTS

1) Yale's Bb Flagellin Patent, 5.618,533 94.4% accurate, earliest, and
100% specific. Or is the best test for Lyme-

The Yale report that goes with the patent (1991):

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1894359&query_hl=2&itool=pubmed_docsum

2) Yale's LYMErix Patent, 5,747,294, Yes I know these by heart

3) Padula, UCONN, 5,620,862 Low or No OspC.

"In another aspect of the invention, Northern blot analysis was used to
detect low levels of OspC mRNA in the North American strain B31. DNA
sequencing of the OspC gene from B31 revealed a 54 bp deletion in the
upstream regulatory region, possibly accounting for the low
transcriptional activity of OspC."

4) Barbour and "Immune System Overhwhelmed," US Patent 6,719,983-

"2.1 Methods of Treatment

"An important aspect of the invention is the recognition that Borrelia
VMP-like sequences recombine at the vls site, with the result that
antigenic variation is virtually limitless. Multiclonal populations
therefore can exist in an infected patient so that immunological
defenses are severely tested if not totally overwhelmed."

That means the Yale/Steere/Dearborn method is useless.

5) Tufts, Huber, 6,689,364

"The present invention provides novel polypeptides which are
substantially free of a B. burgdorferi spirochete or fragments thereof
and which are thus useful in compositions and methods for the treatment
and prevention of B. burgdorferi infection and Lyme disease. In one
preferred embodiment, this invention provides modified OspA
polypeptides and pharmaceutically effective compositions and methods
comprising those polypeptides. Preferred modified OspA polypeptides are
characterized by modifications which diminish and/or ablate their
ability to bind the human MHC allele HLA-DRB1*0401."

Means, basically, "superantigen." (Look up what that means)

6) The RICO Monopoly on testing and LYMErix The Dave Persing, Mayo
Clinic FRAUD Patent-6,045,804 Note the date on the patent. May, 1996.

Read it. It says they had trouble reading their Western Blots in 1006
in vaccinated people.

Here is Yale's Robert Schoen instructing physicians to blow off LYMErix
injured persons and not run any tests on them. This is the 1998 Rahn
and Evans textbook Lyme disease, ACP Key Diseases Series. This was
published even before LYMErix was "approved" by the FDA.

Schoen also demonstrates that he knows that you can't use a strain of
Bb with the OspA-B plasmid in it, because it causes blot smudging or IS
A SUPERANTIGEN???

FROM LYME_CORRUPTICUT http://actionlyme.org/LYME_CORRUPTICUT.htm

27) Martin J. Mattessich President & CEO, Director
"Prior to becoming President and CEO of Agilix, from 1996 to 1999 Mr.
Mattessich was the co-founder of two Yale University-sponsored
biotechnology companies, L2 Diagnostics, LLC (diagnostic serology) and
polyGenomics, Inc. (gene discovery for polygenic diseases) , and a
consultant to CuraGen Corporation, a publicly held genomics company
(pharmaceutical drug ...."

With the blood he intended to get from the L2 Diagnostics-Imugen
nationwide monopoly on testing, they can identify new diseases to
commercialize. AND genetic susceptibilities to diseases.

Persing, Sigal and Molloy, 2000, and the unreadable blots

The vaccine did not come off the market until Karen Forschner of the
Lyme disease Foundation http://www.lyme.org demonstrated the Huber
Tufts patent above to the FDA and that they KNEW this vaccine was
dangerous.

Google